zenuzolac   Click here for help

GtoPdb Ligand ID: 11682

Synonyms: (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid | GIT-027 | GIT-27 | GIT27 | GLS-1027 | GLS1027 | rac-[(5R)-3-phenyl-4,5-dihydro-1,2-oxazol-5-yl]acetic acid | VGX-1027 | VGX1027
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: We obtained the chemical structure for zenuzolac from WHO Proposed list 125 of July 2021, in which it is described as an anti-inflammatory. The INN represents the racemic (rac) mixture of (R) and (S) enantiomers. We show the molecule without specified stereochemistry to represent the mixture. We have mapped this to PubChem CID 10798271. Synonyms from the PubChem entry associate the structure with research code VGX-1027 (VGX Pharmaceuticals). VGX-1027 is an immunomodulatory compound that downregulates proinflammatory cytokine production and NF-κB and MAP kinase activation [1,4-5].

COVID-19: Zenuzolac (re-named as GLS-1027) is being evaluated to determine its potential to reduce SARS-CoV-2-induced pulmonary inflammation (pneumonitis).

zenuzolac is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 58.89
Molecular weight 205.07
XLogP 1.93
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OC(=O)CC1ON=C(C1)c1ccccc1
Isomeric SMILES C1C(ON=C1c1ccccc1)CC(=O)O
InChI InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)
InChI Key MUFJHYRCIHHATF-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Two safety, tolerability and pharmacokinetics clinical studies of VGX-1027 in healthy subjects have been completed (at August 2021).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00760396 Multiple-Dose Study of VGX-1027 in Healthy Subjects Phase 1 Interventional VGX Pharmaceuticals, LLC
NCT00627120 Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects Phase 1 Interventional VGX Pharmaceuticals, LLC
NCT04590547 GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) Phase 2 Interventional GeneOne Life Science, Inc.